Veracyte (VCYT) in Focus: Stock Moves 7% Higher
Veracyte, Inc. VCYT was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $47.85 –$61.88 in the past one-month time frame, witnessed a sharp increase yesterday.
The company has seen two positive estimate revisions in the past few months, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few months, suggesting that more solid trading could be ahead for Veracyte. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Veracyte currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.
Veracyte, Inc. Price
Veracyte, Inc. price | Veracyte, Inc. Quote
A better-ranked stock in the Medical sector is Alimera Sciences, Inc. ALIM, which currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alimera Sciences, Inc. (ALIM) : Free Stock Analysis Report
Veracyte, Inc. (VCYT) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
